# Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

> **NCT05378464** · PHASE1 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 28 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **BIOLOGICAL:** Dendritic Cell (DC1) Vaccine
- **DRUG:** Trastuzumab
- **DRUG:** Pepinemab
- **BIOLOGICAL:** T-Cell therapy

## Key facts

- **NCT ID:** NCT05378464
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-31
- **Primary completion:** 2026-04
- **Final completion:** 2026-12
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05378464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05378464, "Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05378464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*